Akero Therapeutics (AKRO) to Release Earnings on Friday

Key Points

• Akero Therapeutics is set to announce its Q2 2025 earnings on August 8th, with analysts predicting a loss of ($0.95) per share.
• The company recently reported a positive quarterly earnings per share of $0.90, surpassing expectations by $1.91.
• Insider trading activity includes CEO Andrew Cheng selling 37,837 shares at an average price of $54.05, indicating a 6.37% decrease in his holdings.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Friday, August 8th. Analysts expect the company to announce earnings of ($0.95) per share for the quarter.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported $0.90 EPS for the quarter, topping analysts' consensus estimates of ($1.01) by $1.91. On average, analysts expect Akero Therapeutics to post $-4 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Akero Therapeutics Trading Up 1.5%

AKRO traded up $0.72 during midday trading on Monday, reaching $49.09. 220,305 shares of the company were exchanged, compared to its average volume of 1,422,446. The company has a debt-to-equity ratio of 0.03, a quick ratio of 16.80 and a current ratio of 16.80. Akero Therapeutics has a one year low of $21.34 and a one year high of $58.40. The stock has a market capitalization of $3.91 billion, a P/E ratio of -25.18 and a beta of -0.28. The stock's 50-day simple moving average is $52.04 and its 200 day simple moving average is $46.31.

Analyst Ratings Changes

A number of brokerages have issued reports on AKRO. TD Cowen began coverage on Akero Therapeutics in a report on Monday. They set a "buy" rating and a $76.00 target price on the stock. Citigroup reduced their target price on Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Finally, Bank of America raised their target price on Akero Therapeutics from $63.00 to $64.00 and gave the stock a "buy" rating in a report on Tuesday, May 27th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $81.57.

Insider Activity

In other news, insider Timothy Rolph sold 25,000 shares of Akero Therapeutics stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $55.04, for a total transaction of $1,376,000.00. Following the transaction, the insider owned 169,721 shares in the company, valued at $9,341,443.84. The trade was a 12.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Andrew Cheng sold 37,837 shares of Akero Therapeutics stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $54.05, for a total value of $2,045,089.85. Following the transaction, the chief executive officer owned 556,487 shares in the company, valued at $30,078,122.35. This trade represents a 6.37% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 235,906 shares of company stock worth $11,862,790 in the last 90 days. Corporate insiders own 7.07% of the company's stock.

Institutional Investors Weigh In On Akero Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of AKRO. Royal Bank of Canada raised its position in Akero Therapeutics by 14.0% in the 1st quarter. Royal Bank of Canada now owns 26,602 shares of the company's stock valued at $1,077,000 after buying an additional 3,263 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Akero Therapeutics by 15.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,818 shares of the company's stock worth $1,943,000 after purchasing an additional 6,376 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Akero Therapeutics by 6.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 488,392 shares of the company's stock worth $19,770,000 after purchasing an additional 30,868 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Akero Therapeutics by 53.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 109,909 shares of the company's stock worth $4,449,000 after purchasing an additional 38,458 shares during the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.